EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pathophysiology of Placenta in Antiphospholipid Syndrome

Anca Bobircă, Ana Dumitrache, Cristina Alexandru, Anca Florescu, George Ciobotaru, Florin Bobircă, Romina-Marina Sima, Cristian Poalelungi, Mihai Bojincă, Ioan Ancuța

Physiologia · 2022

DOI: 10.3390/physiologia2030007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Physiologia, 2022. Verfasst von Anca Bobircă und 9 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by clinical manifestations caused by arterial or venous thrombosis and pregnancy conditions such as recurrent miscarriage, fetal death, or premature birth in the presence of antiphospholipid antibodies. The obstetrical manifestations are strongly related to the placental alterations. The aim of this review is to summarize the latest data on pathophysiology of obstetrical APS, emphasizing the disturbance of the placentation process. Due to a lack of extravillous trophoblasts to properly reconstruct the spiral arteries, APS causes hypoxic or ischemic injury or high-speed blood flow that damages the placenta. This results in decreased or interrupted maternal blood flow to the placenta and a lack of nutrients for the fetus. Antiphospholipid antibodies can lower the proliferation and infiltration of the extravillous trophoblasts. The placental mal-perfusion causes the release of antiangiogenic substances such as soluble fms-like tyrosine kinase-1 and soluble endoglin. Placental growth factor and vascular endothelial growth factor (VEGF) may be sequestered by sFlt1 and blocked from binding to trophoblast and endothelial cell VEGF receptors, inhibiting their proangiogenic effects. Preeclampsia is the clinical result from a lack of angiogenic factors needed for endothelial vascular homeostasis due to an excess of sFlt1 in the maternal circulation.

Zitieren

APA

Bobircă, A., Dumitrache, A., Alexandru, C., Florescu, A., Ciobotaru, G., Bobircă, F., Sima, R., Poalelungi, C., Bojincă, M., & Ancuța, I. (2022). Pathophysiology of Placenta in Antiphospholipid Syndrome. Physiologia. https://doi.org/10.3390/physiologia2030007

Vancouver

Bobircă A, Dumitrache A, Alexandru C, Florescu A, Ciobotaru G, Bobircă F, et al. Pathophysiology of Placenta in Antiphospholipid Syndrome. Physiologia. 2022. doi:10.3390/physiologia2030007

BibTeX
@article{Bobirc2022,
  author = {Bobircă, Anca and Dumitrache, Ana and Alexandru, Cristina and Florescu, Anca and Ciobotaru, George and Bobircă, Florin and Sima, Romina-Marina and Poalelungi, Cristian and Bojincă, Mihai and Ancuța, Ioan},
  title = {Pathophysiology of Placenta in Antiphospholipid Syndrome},
  journal = {Physiologia},
  year = {2022},
  doi = {10.3390/physiologia2030007}
}
Kostenlos starten →